Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Universal Influenza A DNA vaccine
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Epidermal
01
Overview
Orlance's Universal Influenza A DNA vaccine is a nucleic acid-based prophylactic designed to provide broad protection against multiple strains of the Influenza A virus. It utilizes the MACH-1 epidermal powdered gene gun platform, which delivers DNA-coated microparticles directly into the epidermal layer of the skin. This method is designed to trigger a robust immune response, including both humoral (antibody) and cellular (T-cell) immunity, by targeting the skin's rich population of antigen-presenting cells. The vaccine is currently in the IND-enabling phase of development.
- Other names
- MACH-1 + UFluA-Orlance-Influenza A virus-DNA vaccine-nucleic acid vaccine-epidermal-Influenza A (universal)Universal Influenza A VaccineUniversal Influenza A DNA vaccineMACH-1 Universal Influenza A DNA vaccineMACH1 Universal Influenza A DNA vaccineMACH 1 Universal Influenza A DNA vaccine
Beyond the preview
Go deeper on Universal Influenza A DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Universal Influenza A DNA vaccine.